Lung Deposition of a Nacystelyn Metered Dose Inhaler Formulation

1993 ◽  
Vol 6 (1) ◽  
pp. 37-44 ◽  
Author(s):  
J.G. HARDY ◽  
M.L. EVERARD ◽  
M. COFFINER ◽  
J. FOSSION
Keyword(s):  
Lung Deposition ◽  
Dose Inhaler ◽  
Metered Dose Inhaler ◽  
Metered Dose

scholarly journals Lung deposition of budesonide from Turbuhaler® is twice that from a pressurized metered-dose inhaler (P-MDI).

1995 ◽  
Vol 8 (12) ◽  
pp. 2194-2196 ◽  
Author(s):  
R.W. Fuller ◽  
R.K. Sharma ◽  
A. Cripps ◽  
R. Liard ◽  
M. Aubier ◽  
...  
Keyword(s):  
Lung Deposition ◽  
Dose Inhaler ◽  
Metered Dose Inhaler ◽  
Metered Dose ◽  
Pressurized Metered Dose Inhaler

Influence of Particle Size and Patient Dosing Technique on Lung Deposition of HFA-Beclomethasone from a Metered Dose Inhaler

2005 ◽  
Vol 18 (4) ◽  
pp. 379-385 ◽  
Author(s):  
Chet L. Leach ◽  
Patricia J. Davidson ◽  
Bruce E. Hasselquist ◽  
Robert J. Boudreau
Keyword(s):  
Particle Size ◽  
Lung Deposition ◽  
Dose Inhaler ◽  
Metered Dose Inhaler ◽  
Metered Dose

scholarly journals P238 The Effect Of Inhalation Duration On Lung Deposition With A Pressurised Metered-dose Inhaler (pmdi)

Thorax ◽  
2014 ◽  
Vol 69 (Suppl 2) ◽  
pp. A181-A181
Author(s):  
C. Van Holsbeke ◽  
J. Marshall ◽  
J. De Backer ◽  
W. Vos
Keyword(s):  
Lung Deposition ◽  
Dose Inhaler ◽  
Metered Dose Inhaler ◽  
Metered Dose ◽  
Pressurised Metered Dose Inhaler

Radio Labelling of Drugs in a Metered Dose Inhaler (MDI) and Lung Deposition in Human Subjects

1994 ◽  
Vol 7 (2) ◽  
pp. 173-176 ◽  
Author(s):  
ANDREAS HAMMERMAIER ◽  
ANDREA BIDLINGMAIER ◽  
JOSEF WAITZINGER ◽  
ROLAND STECHERT ◽  
HARALD WENSKE ◽  
...  
Keyword(s):  
Human Subjects ◽  
Lung Deposition ◽  
Dose Inhaler ◽  
Metered Dose Inhaler ◽  
Metered Dose ◽  
Radio Labelling

scholarly journals Use of functional respiratory imaging to characterize the effect of inhalation profile and particle size on lung deposition of inhaled corticosteroid/long-acting β2-agonists delivered via a pressurized metered-dose inhaler

2018 ◽  
Vol 12 ◽  
pp. 175346661876094 ◽  
Author(s):  
Cedric Van Holsbeke ◽  
Jan De Backer ◽  
Wim Vos ◽  
Jonathan Marshall
Keyword(s):  
Three Dimensional ◽  
Lung Deposition ◽  
Dose Inhaler ◽  
Metered Dose Inhaler ◽  
Inhaled Corticosteroid ◽  
Inhaled Drugs ◽  
Flow Rates ◽  
Metered Dose ◽  
Three Dimensional Models ◽  
Long Acting

Background: Functional respiratory imaging (FRI) uses three-dimensional models of human lungs and computational fluid dynamics to simulate functional changes within airways and predict the deposition of inhaled drugs. This study used FRI to model the effects of different patient inhalation and drug formulation factors on lung deposition of an inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) combination, administered by a pressurized metered-dose inhaler. Methods: Three-dimensional models of the lungs of six patients with asthma (mean forced expiratory volume in 1 s, 83%), treated with an ICS/LABA, were included. FRI modelling was used to simulate (1) the effects on lung deposition of inhalation duration and particle size [fine particle fraction (FPF), proportion of particles <5 µm; and mass median aerodynamic diameter (MMAD), average size of inhalable particles]; (2) deposition of fluticasone propionate/formoterol (FP/FORM) 125/5 µg; and (3) how inhalation profiles and flow rates affected FP/FORM deposition. Results: Total lung depositions (TLDs) following 1-, 3- and 5-s inhalations were 22.8%, 36.1% and 41.6% (metered dose), respectively, and central-to-peripheral deposition (C:P) ratios were 1.81, 0.86 and 0.61, respectively. TLD increased with increasing FPF, from ~8% at 10% FPF to ~36% at 40% FPF (metered dose); by contrast, MMAD had little effect on TLD, which was similar across MMADs (1.5–4.5 µm) at each FPF. FP/FORM deposited throughout central and peripheral airways with gradual (sinusoidal) and sharp (rapid) inhalations. TLD ranged from 35.8 to 44.0% (metered dose) for gradual and sharp inhalations at 30 and 60 L/min mean flow rates. Conclusions: These data provide important insights into the potential effects of inhalation characteristics (inhalation profile and duration) and aerosol formulation (FPF) on lung deposition of inhaled therapies. FRI thus represents a useful alternative to scintigraphy techniques. Future FRI studies will further our understanding of the deposition of inhaled drugs and help improve the management of asthma.

Sign in / Sign up

Export Citation Format

Share Document